Hematology News

September is National Sickle Cell Awareness Month.

The FDA has approved mepolizumab for certain adults and children with hypereosinophilic syndrome, according to a press release.

The addition of eltrombopag to standard immunosuppressive therapy appeared safe and increased response rates among transplant-ineligible patients with severe aplastic anemia, according to results of the randomized phase 3 RACE trial.

An IV injection of BIVV001 induced high sustained factor VIII activity levels among men with severe hemophilia A, according to results of a phase 1/phase 2 open-label trial published in The New England Journal of Medicine.

Hematopoietic stem cell transplantation has proved effective for the treatment of many inherited nonmalignant disorders among children.

The COVID-19 pandemic has prompted a flurry of scientific studies of various potential treatments and vaccines for the novel coronavirus.

The FDA granted rare pediatric disease designation to EDIT-301, an investigational autologous cell therapy for the treatment of sickle cell disease, according to the agent’s manufacturer.

On Sunday, the FDA authorized the emergency use of convalescent plasma as a therapy for patients hospitalized with COVID-19, saying the “known and potential benefits” of the technique outweigh any risks.

New guidelines issued by ASH and published in Blood Advances aim to support patients, clinicians and other health care professionals in their decisions about treatment for older adults with acute myeloid leukemia.

Receiving medical marijuana appeared associated with reduced hospital admission rates among patients with sickle cell disease, according to results of a retrospective study published in Blood Advances.